
### [MONDO:0020076](http://purl.obolibrary.org/obo/MONDO_0020076)
**Label:** myeloproliferative neoplasm

**Subclasses:** [MONDO:0008040](http://purl.obolibrary.org/obo/MONDO_0008040) (transient myeloproliferative syndrome (disease)), [MONDO:0011173](http://purl.obolibrary.org/obo/MONDO_0011173) (thrombocythemia 2), [MONDO:0013794](http://purl.obolibrary.org/obo/MONDO_0013794) (thrombocythemia 3), [MONDO:0017833](http://purl.obolibrary.org/obo/MONDO_0017833) (primary hypereosinophilic syndrome), [MONDO:0009692](http://purl.obolibrary.org/obo/MONDO_0009692) (primary myelofibrosis), [MONDO:0015687](http://purl.obolibrary.org/obo/MONDO_0015687) (chronic eosinophilic leukemia), [MONDO:0009891](http://purl.obolibrary.org/obo/MONDO_0009891) (polycythemia vera), [MONDO:0019111](http://purl.obolibrary.org/obo/MONDO_0019111) (familial thrombocytosis), [MONDO:0019452](http://purl.obolibrary.org/obo/MONDO_0019452) (chronic myeloproliferative disease, unclassifiable), [MONDO:0008554](http://purl.obolibrary.org/obo/MONDO_0008554) (thrombocythemia 1), [MONDO:0015691](http://purl.obolibrary.org/obo/MONDO_0015691) (hypereosinophilic syndrome), [MONDO:0019451](http://purl.obolibrary.org/obo/MONDO_0019451) (chronic neutrophilic leukemia), [MONDO:0005029](http://purl.obolibrary.org/obo/MONDO_0005029) (essential thrombocythemia), [MONDO:0007546](http://purl.obolibrary.org/obo/MONDO_0007546) (myeloproliferative disorder, chronic, with eosinophilia), [MONDO:0010809](http://purl.obolibrary.org/obo/MONDO_0010809) (familial chronic myelocytic leukemia-like syndrome), [MONDO:0011996](http://purl.obolibrary.org/obo/MONDO_0011996) (chronic myelogenous leukemia), [MONDO:0010301](http://purl.obolibrary.org/obo/MONDO_0010301) (THCYTX), [MONDO:0011895](http://purl.obolibrary.org/obo/MONDO_0011895) (idiopathic hypereosinophilic syndrome), [MONDO:0014837](http://purl.obolibrary.org/obo/MONDO_0014837) (hereditary thrombocytopenia with early-onset myelofibrosis), [MONDO:0017835](http://purl.obolibrary.org/obo/MONDO_0017835) (lymphocytic hypereosinophilic syndrome), [MONDO:0017834](http://purl.obolibrary.org/obo/MONDO_0017834) (secondary hypereosinophilic syndrome), 

**Corr. equiv. classes:** [OMIM:187950](http://purl.obolibrary.org/obo/OMIM_187950), [OMIM:601977](http://purl.obolibrary.org/obo/OMIM_601977), [Orphanet:86830](http://www.orpha.net/ORDO/Orphanet_86830), [Orphanet:3318](http://www.orpha.net/ORDO/Orphanet_3318), [OMIM:600080](http://purl.obolibrary.org/obo/OMIM_600080), [OMIM:616937](http://purl.obolibrary.org/obo/OMIM_616937), [Orphanet:168940](http://www.orpha.net/ORDO/Orphanet_168940), [Orphanet:71493](http://www.orpha.net/ORDO/Orphanet_71493), [Orphanet:314970](http://www.orpha.net/ORDO/Orphanet_314970), [Orphanet:480851](http://www.orpha.net/ORDO/Orphanet_480851), [Orphanet:314950](http://www.orpha.net/ORDO/Orphanet_314950), [OMIM:159595](http://purl.obolibrary.org/obo/OMIM_159595), [Orphanet:86829](http://www.orpha.net/ORDO/Orphanet_86829), [Orphanet:3260](http://www.orpha.net/ORDO/Orphanet_3260), [OMIM:300331](http://purl.obolibrary.org/obo/OMIM_300331), [OMIM:263300](http://purl.obolibrary.org/obo/OMIM_263300), [OMIM:131440](http://purl.obolibrary.org/obo/OMIM_131440), [OMIM:254450](http://purl.obolibrary.org/obo/OMIM_254450), [OMIM:614521](http://purl.obolibrary.org/obo/OMIM_614521), [Orphanet:420611](http://www.orpha.net/ORDO/Orphanet_420611), [Orphanet:168956](http://www.orpha.net/ORDO/Orphanet_168956), [Orphanet:729](http://www.orpha.net/ORDO/Orphanet_729), [OMIM:607685](http://purl.obolibrary.org/obo/OMIM_607685), [Orphanet:824](http://www.orpha.net/ORDO/Orphanet_824), [OMIM:608232](http://purl.obolibrary.org/obo/OMIM_608232), [Orphanet:521](http://www.orpha.net/ORDO/Orphanet_521), [Orphanet:314962](http://www.orpha.net/ORDO/Orphanet_314962), 

**Class expressions from DL-Learner:**

- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0010978](http://purl.obolibrary.org/obo/HP_0010978) (Abnormality of immune system physiology))) 54.80%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0001903](http://purl.obolibrary.org/obo/HP_0001903) (Anemia))) 51.15%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0012374](http://purl.obolibrary.org/obo/HP_0012374) (Abnormality of the globe))) 49.65%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0012372](http://purl.obolibrary.org/obo/HP_0012372) (Abnormal eye morphology))) 49.65%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0000234](http://purl.obolibrary.org/obo/HP_0000234) (Abnormality of the head))) 49.65%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0000152](http://purl.obolibrary.org/obo/HP_0000152) (Abnormality of head or neck))) 49.65%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0012649](http://purl.obolibrary.org/obo/HP_0012649) (Increased inflammatory response))) 48.32%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0012647](http://purl.obolibrary.org/obo/HP_0012647) (Abnormal inflammatory response))) 48.32%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0011013](http://purl.obolibrary.org/obo/HP_0011013) (Abnormality of carbohydrate metabolism/homeostasis))) 48.32%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0001627](http://purl.obolibrary.org/obo/HP_0001627) (Abnormal heart morphology))) 48.32%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0000271](http://purl.obolibrary.org/obo/HP_0000271) (Abnormality of the face))) 48.32%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0011849](http://purl.obolibrary.org/obo/HP_0011849) (Abnormal bone ossification))) 47.12%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0004348](http://purl.obolibrary.org/obo/HP_0004348) (Abnormality of bone mineral density))) 47.12%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0003330](http://purl.obolibrary.org/obo/HP_0003330) (Abnormal bone structure))) 47.12%
- [HP:0001894](http://purl.obolibrary.org/obo/HP_0001894) (Thrombocytosis) and (not ([HP:0000818](http://purl.obolibrary.org/obo/HP_0000818) (Abnormality of the endocrine system))) 47.12%


